Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2023

23-08-2023 | Thrombocytopenia | Letter to the Editor

Successful use of thrombopoietin analogs in thrombocytopenia associated with MYH-9 mutation

Authors: María Louzao, María Teresa Vargas, Emma Meseguer, Begoña Pedrote Amador, Jose Antonio Perez Simón, María Eva Mingot-Castellano

Published in: Annals of Hematology | Issue 11/2023

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Nurden P, Stritt S, Favier R, Nurden AT (2021) Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica 106(2):337–350CrossRefPubMed
3.
4.
Paciullo F, Bury L, Gresele P (2020) Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer. Int J Hematol 112(5):725–727CrossRefPubMed
5.
Lassandro G, Carriero F, Noviello D, Palladino V, Del Vecchio GC, Faienza MF et al (2022) Successful eltrombopag therapy in a child with MYH9-related inherited thrombocytopenia. Children 9(12):1839CrossRefPubMedPubMedCentral
6.
Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA (2013) First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics 132:e793–e795CrossRefPubMed
7.
Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T et al (2010) Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 116(26):5832–5837CrossRefPubMed
8.
Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C et al (2005) Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet 14:3169–3178CrossRefPubMed
9.
Bury L, Megy K, Stephens JC, Grassi L, Greene D, Gleadall N et al (2020) Next-generation sequencing for the diagnosis of MYH9-RD: predicting pathogenic variants. Human Mutat 41:277–290CrossRef
10.
Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V et al (2008) Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29:409–417CrossRefPubMed
Metadata
Title
Successful use of thrombopoietin analogs in thrombocytopenia associated with MYH-9 mutation
Authors
María Louzao
María Teresa Vargas
Emma Meseguer
Begoña Pedrote Amador
Jose Antonio Perez Simón
María Eva Mingot-Castellano
Publication date
23-08-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05386-0

Other articles of this Issue 11/2023

Annals of Hematology 11/2023 Go to the issue

Original Article

Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia

Original Article

Bleeding risk assessment in immune thrombocytopenia

Letter to the Editor

Hemophagocytosis by multinucleated leukemic blasts, basophilia, and micromegakaryocytes in AML with TLS::ERG

Original Article

Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia

Original Article

Alternative treatment modality for severe aplastic anemia in a resource-limited setting: a single-institution prospective cohort study from Upper Egypt

Original Article

Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits